MX2022002970A - Composicion de tableta de racecadotrilo con sabor enmascarado y proceso para su preparacion. - Google Patents

Composicion de tableta de racecadotrilo con sabor enmascarado y proceso para su preparacion.

Info

Publication number
MX2022002970A
MX2022002970A MX2022002970A MX2022002970A MX2022002970A MX 2022002970 A MX2022002970 A MX 2022002970A MX 2022002970 A MX2022002970 A MX 2022002970A MX 2022002970 A MX2022002970 A MX 2022002970A MX 2022002970 A MX2022002970 A MX 2022002970A
Authority
MX
Mexico
Prior art keywords
racecadotril
tablet composition
preparation
taste masked
racecadotril tablet
Prior art date
Application number
MX2022002970A
Other languages
English (en)
Inventor
Mahendra B Chaudhari
Anita Kunal Shahane
Original Assignee
Athena Pharmaceutiques Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athena Pharmaceutiques Sas filed Critical Athena Pharmaceutiques Sas
Publication of MX2022002970A publication Critical patent/MX2022002970A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición de comprimidos de Racecadotril con sabor enmascarado que comprende: 13 a 15 % p/p de Racecadotrilo; 0.3 a 0.4 % p/p de polivinilpirrolidona; 3 a 5 % p/p de sílice coloidal anhidra; 50 a 60 % p/p de manitol; 0.5 a 1% p/p de polietilenglicol; 4 a 5 % de copolímero de metacrilato de aminoalquilo; 5 a 10 % p/p de celulosa microcristalina; y 3 a 7 % p/p de celulosa croscararmelosa; donde él % p/p es con respecto al peso total de la composición.
MX2022002970A 2021-03-12 2022-03-10 Composicion de tableta de racecadotrilo con sabor enmascarado y proceso para su preparacion. MX2022002970A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN202111010560 2021-03-12

Publications (1)

Publication Number Publication Date
MX2022002970A true MX2022002970A (es) 2022-09-13

Family

ID=80446848

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002970A MX2022002970A (es) 2021-03-12 2022-03-10 Composicion de tableta de racecadotrilo con sabor enmascarado y proceso para su preparacion.

Country Status (4)

Country Link
EP (1) EP4056171A1 (es)
KR (1) KR20220128290A (es)
CN (1) CN115068431A (es)
MX (1) MX2022002970A (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2480747A1 (fr) 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
CN102151247A (zh) 2000-06-23 2011-08-17 生物计划公司 包含外消旋卡朵曲的干粉制剂
CN1506043A (zh) 2002-12-11 2004-06-23 成都博瑞医药科技开发有限公司 含有卡多曲的快速崩解片剂
TR201801726T4 (tr) 2012-12-26 2018-03-21 Ilko Ilac Sanayi Veticaret A S Rasekadotri̇l ve farmasöti̇k bi̇leşi̇mleri̇.

Also Published As

Publication number Publication date
EP4056171A1 (en) 2022-09-14
KR20220128290A (ko) 2022-09-20
CN115068431A (zh) 2022-09-20

Similar Documents

Publication Publication Date Title
ES2582646T3 (es) Formulación de comprimido recubierto y método
TWI350170B (en) Treating agent for glaucoma comprising rho kinase inhibitor and prostaglandin
PL1496870T3 (pl) Postać leku i sposób jej wytwarzania
MY196599A (en) Pharmaceutical compositons comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
TW200745111A (en) New compounds
WO2022125616A8 (en) Dialkyl tryptamines and their therapeutic uses
ES2331046T1 (es) Formulacion de liberacion controlada.
EA200601418A1 (ru) ПРОИЗВОДНЫЕ 1Н-ТИЕНО [2,3-с] ПИРАЗОЛА, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ИСПОЛЬЗОВАНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ
TWI264311B (en) Method for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency
TW200606164A (en) New compounds
MX2023003576A (es) Compuesto como inhibidor de la akt cinasa.
JO2684B1 (en) Quinoline antibacterial derivatives
NZ599762A (en) Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
AR125250A1 (es) Composiciones de psilocibina, procedimientos de fabricación y procedimientos de uso de las mismas
MX2022002970A (es) Composicion de tableta de racecadotrilo con sabor enmascarado y proceso para su preparacion.
IN2014MN02364A (es)
NZ767228A (en) Kv7 channel activators compositions and methods of use
MX2024003459A (es) Metodos de tratamiento de trastornos metabolicos.
MY195576A (en) Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof
SE0102440D0 (sv) New compound
RU95110762A (ru) Производные 5-гидразинохинолона, композиция для лечения или профилактики инфекционного заболевания, способ лечения или профилактики
MX2023012521A (es) Formas en estado solido de (s)-n-(3-(2-((r)-1-hidroxipropano-2-il) amino)-6-morfolinopiridin-4-il)-4-metilfenil)-3-(2,2,2-trifluoroe til)pirrolidin-1-carboxamida y sales de las mismas.
TW200509995A (en) Pharmaceutical composition as solid dosage form and method for manufacturing thereof
JO2725B1 (en) Quinoline antibacterial derivatives
MX2023006193A (es) Compuesto triciclico fusionado, metodo de preparacion y aplicacion del mismo en medicina.